Eric Greer

Dr. Eric Greer

Division of Newborn Medicine, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2012 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
Eric GreerEric Greer
Eric Greer
YSYang Shi
Yang Shi


1 October 2007 in Current Biology
Verified
Journal Article
Closed access
Eric GreerEric Greer
Eric Greer
DDDara Dowlatshahi
Dara Dowlatshahi
MBMax R. Banko
Max R. Banko
JVJudit Villen
Judit Villen
KHKimmi Hoang
Kimmi Hoang
ABAnne Brunet
Anne Brunet

1 October 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Eric GreerEric Greer
Eric Greer
POPhilip R. Oskoui
Philip R. Oskoui
MBMax R. Banko
Max R. Banko
JMJay M. Maniar
Jay M. Maniar
MGMelanie P. Gygi
Melanie P. Gygi
ABAnne Brunet
Anne Brunet
The maintenance of homeostasis throughout an organism's life span requires constant adaptation to changes in energy levels. The AMP-activated protein kinase (AMPK) plays a critical role in the cellular responses to low energy levels by switching off energy-consuming pathways and switching on energy-producing pathways. However, the transcriptional mechanisms by which AMPK acts to adjust cellular energy levels are not entirely characterized. Here, we find that AMPK directly regulates mammalian FOXO3, a member of the FOXO family of Forkhead transcription factors known to promote resistance to oxidative stress, tumor suppression, and longevity. We show that AMPK phosphorylates human FOXO3 at six previously unidentified regulatory sites. Phosphorylation by AMPK leads to the activation of FOXO3 transcriptional activity without affecting FOXO3 subcellular localization. Using a genome-wide microarray analysis, we identify a set of target genes that are regulated by FOXO3 when phosphorylated at these six regulatory sites in mammalian cells. The regulation of FOXO3 by AMPK may play a crucial role in fine tuning gene expression programs that control energy balance and stress resistance in cells throughout life.

1 May 2015 in Cell
Verified
Journal Article
Closed access
Eric GreerEric Greer
Eric Greer
MBMario Andres Blanco
Mario Andres Blanco
LGLei Gu
Lei Gu
ESErdem Sendinc
Erdem Sendinc
JLJianzhao Liu
Jianzhao Liu
YSYang Shi
Yang Shi

16 October 2005 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RORobert S Ohgami
Robert S Ohgami
DCDean R Campagna
Dean R Campagna
Eric GreerEric Greer
Eric Greer
BABrendan Antiochos
Brendan Antiochos
AMAlice McDonald
Alice McDonald
MFMark D Fleming
Mark D Fleming
The reduction of iron is an essential step in the transferrin (Tf) cycle, which is the dominant pathway for iron uptake by red blood cell precursors. A deficiency in iron acquisition by red blood cells leads to hypochromic, microcytic anemia. Using a positional cloning strategy, we identified a gene, six-transmembrane epithelial antigen of the prostate 3 (Steap3), responsible for the iron deficiency anemia in the mouse mutant nm1054. Steap3 is expressed highly in hematopoietic tissues, colocalizes with the Tf cycle endosome and facilitates Tf-bound iron uptake. Steap3 shares homology with F420H2:NADP+ oxidoreductases found in archaea and bacteria, as well as with the yeast FRE family of metalloreductases. Overexpression of Steap3 stimulates the reduction of iron, and mice lacking Steap3 are deficient in erythroid ferrireductase activity. Taken together, these findings indicate that Steap3 is an endosomal ferrireductase required for efficient Tf-dependent iron uptake in erythroid cells.